In vivo generation of β-cell-like cells from CD34+ cells differentiated from human embryonic stem cells

Our data suggest that hESC-derived CD34+ cells have a potential for long-term in vivo endocrine cellular activity that could prove useful in regenerative medicine. Because the same cell population has previously been shown to contain hematopoietic potential, it could be used for the induction of immunological tolerance and bone marrow chimerism prior to cellular therapy for diabetes.